Evofem Biosciences Inc EVFM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EVFM is a good fit for your portfolio.
News
-
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
-
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
-
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
-
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.02
- 52-Week Range
- $0.01–3.75
- Bid/Ask
- $0.01 / $0.02
- Market Cap
- $769,486.78
- Volume/Avg
- 555,899 / 860,384
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.80
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
- Website
- https://www.evofem.com
Valuation
|
Metric
|
EVFM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.80 |
Price/Cash Flow | — |
Price/Earnings
EVFM
Financial Strength
|
Metric
|
EVFM
|
|---|---|
Quick Ratio | 0.08 |
Current Ratio | 0.13 |
Interest Coverage | — |
Quick Ratio
EVFM
Profitability
|
Metric
|
EVFM
|
|---|---|
Return on Assets (Normalized) | −105.63% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
EVFM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Khbwtyph | Ssdn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tjqkmfzy | Wfmstg | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Znsmrmh | Rmvfb | $97.8 Bil | |
MRNA
| Moderna Inc | Qdmrsrt | Zmkfs | $41.3 Bil | |
ARGX
| argenx SE ADR | Tdwjvwfrb | Sfhmn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ppdpxmqyx | Phf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tgrjvsm | Mxhsmtt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wsdxynvc | Zzsyvt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cyqnyhdxgf | Dmjkkx | $12.5 Bil | |
INCY
| Incyte Corp | Fjtzwwgk | Qkblc | $11.6 Bil |